• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物性高钾血症:老问题与新诱因

Drug-induced hyperkalemia: old culprits and new offenders.

作者信息

Perazella M A

机构信息

Section of Nephrology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

出版信息

Am J Med. 2000 Sep;109(4):307-14. doi: 10.1016/s0002-9343(00)00496-4.

DOI:10.1016/s0002-9343(00)00496-4
PMID:10996582
Abstract

Prescribed medications, over-the-counter drugs, and nutritional supplements are used by many patients. Although most of these products are well tolerated, drug-induced hyperkalemia may develop in patients with underlying renal impairment or other abnormalities in potassium handling. Drug-induced hyperkalemia most often occurs from impaired renal potassium excretion. However, disturbed cellular uptake of a potassium load as well as excessive ingestion or infusion of potassium-containing substances may also occur. Physicians must be aware of medications that can precipitate hyperkalemia, how these drugs induce alterations in potassium homeostasis, and the patient characteristics that increase the risk of hyperkalemia.

摘要

许多患者会使用处方药、非处方药和营养补充剂。虽然这些产品大多耐受性良好,但在有潜在肾功能损害或钾代谢其他异常的患者中,可能会发生药物性高钾血症。药物性高钾血症最常见于肾钾排泄受损。然而,钾负荷的细胞摄取紊乱以及含钾物质的过量摄入或输注也可能发生。医生必须了解可引发高钾血症的药物、这些药物如何引起钾稳态改变以及增加高钾血症风险的患者特征。

相似文献

1
Drug-induced hyperkalemia: old culprits and new offenders.药物性高钾血症:老问题与新诱因
Am J Med. 2000 Sep;109(4):307-14. doi: 10.1016/s0002-9343(00)00496-4.
2
Life-threatening hyperkalemia from nutritional supplements: uncommon or undiagnosed?营养补充剂导致的危及生命的高钾血症:罕见还是未被诊断?
Am J Emerg Med. 2011 Nov;29(9):1237.e1-2. doi: 10.1016/j.ajem.2010.08.029. Epub 2010 Nov 13.
3
Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.老年人高钾血症:药物会加剧受损的钾稳态。
J Gen Intern Med. 1997 Oct;12(10):646-56. doi: 10.1046/j.1525-1497.1997.07128.x.
4
Drug-induced hyperkalemia.药物性高钾血症
Drug Saf. 2014 Sep;37(9):677-92. doi: 10.1007/s40264-014-0196-1.
5
Hyperkalaemic paralysis.高钾性麻痹
Age Ageing. 2003 Jan;32(1):114-5. doi: 10.1093/ageing/32.1.114.
6
Hazards of non-prescription potassium supplements.非处方钾补充剂的危害。
Lancet. 1984 Mar 3;1(8375):513-4. doi: 10.1016/s0140-6736(84)92883-6.
7
Drug-induced hyperkalemia.药物性高钾血症
Medicine (Baltimore). 1985 Nov;64(6):357-70. doi: 10.1097/00005792-198511000-00001.
8
Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.血管紧张素转化酶抑制剂和血管紧张素受体阻滞剂相关的高钾血症。
Cardiovasc Ther. 2012 Jun;30(3):e156-66. doi: 10.1111/j.1755-5922.2010.00258.x. Epub 2011 Jan 26.
9
Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.对服用易致高钾血症药物的炔雌醇/屈螺酮使用者进行血清钾监测:医生的依从性以及知识与态度调查
Contraception. 2007 Feb;75(2):101-7. doi: 10.1016/j.contraception.2006.08.011. Epub 2006 Oct 3.
10
Drug-induced abnormalities of potassium metabolism.药物引起的钾代谢异常。
Pol Arch Med Wewn. 2008 Jul-Aug;118(7-8):431-4.

引用本文的文献

1
The burden of hyperkalaemia in chronic kidney disease: a systematic literature review.慢性肾脏病中高钾血症的负担:一项系统文献综述
Clin Kidney J. 2025 Apr 29;18(5):sfaf127. doi: 10.1093/ckj/sfaf127. eCollection 2025 May.
2
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings.扩大钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病患者不同临床场景中的应用。
Cells. 2025 May 2;14(9):668. doi: 10.3390/cells14090668.
3
Drug-Event Pairs as Indicators for the Detection of Adverse Drug Reactions during Hospitalization in Routinely Collected Electronic Data Sources.
作为常规收集的电子数据源中住院期间药物不良反应检测指标的药物-事件对
Clin Pharmacol Ther. 2025 Jun;117(6):1811-1819. doi: 10.1002/cpt.3635. Epub 2025 Mar 18.
4
Impact of hyperkalaemia on renin-angiotensin-aldosterone (RAAS) inhibitor reduction or withdrawal following hospitalisation.高钾血症对住院后肾素-血管紧张素-醛固酮(RAAS)抑制剂减量或停用的影响。
Clin Exp Med. 2024 Dec 21;25(1):16. doi: 10.1007/s10238-024-01531-9.
5
Retrospective evaluation of risk factors for worsening renal function after angiotensin-converting enzyme inhibitor treatment in dogs.犬类接受血管紧张素转换酶抑制剂治疗后肾功能恶化危险因素的回顾性评估。
J Vet Intern Med. 2025 Jan-Feb;39(1):e17252. doi: 10.1111/jvim.17252. Epub 2024 Nov 20.
6
Risk of developing hyperkalemia in patients with hypertension treated with combination antihypertensive therapy - a retrospective register-based study.联合降压治疗的高血压患者发生高钾血症的风险——一项基于登记资料的回顾性研究
Hypertens Res. 2025 Jan;48(1):378-387. doi: 10.1038/s41440-024-01894-2. Epub 2024 Oct 31.
7
Transient secondary pseudo-hypoaldosteronism in infants with urinary tract infections: systematic literature review.尿路感染婴儿一过性假性醛固酮减少症:系统文献复习。
Eur J Pediatr. 2024 Oct;183(10):4205-4214. doi: 10.1007/s00431-024-05676-3. Epub 2024 Jul 10.
8
Duplication errors due to brand name confusion; It is not always the name-Short case series.由于品牌名称混淆导致的重复错误;这并非总是名称简短的病例系列。
Clin Case Rep. 2023 Sep 14;11(9):e7795. doi: 10.1002/ccr3.7795. eCollection 2023 Sep.
9
Understanding and Treatment Strategies of Hypertension and Hyperkalemia in Chronic Kidney Disease.慢性肾脏病中高血压与高钾血症的认识及治疗策略
Electrolyte Blood Press. 2023 Jun;21(1):24-33. doi: 10.5049/EBP.2023.21.1.24. Epub 2023 Jun 27.
10
Hyperkalemia: Prevalence, Predictors and Emerging Treatments.高钾血症:患病率、预测因素及新出现的治疗方法。
Cardiol Ther. 2023 Mar;12(1):35-63. doi: 10.1007/s40119-022-00289-z. Epub 2022 Dec 12.